PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.81%
EBIT growth of 35.81% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
36.41%
Operating income growth of 36.41% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
439.57%
Net income growth of 439.57% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
440.81%
EPS growth of 440.81% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
440.81%
Diluted EPS growth of 440.81% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
681.03%
OCF growth of 681.03% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
681.03%
FCF growth of 681.03% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1209.68%
OCF/share CAGR of 1209.68% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
1209.68%
OCF/share CAGR of 1209.68% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
1209.68%
3Y OCF/share growth of 1209.68% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
934.70%
Net income/share CAGR of 934.70% while Biotechnology median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
934.70%
5Y net income/share CAGR > 1.5x Biotechnology median of 24.21%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
934.70%
3Y net income/share CAGR > 1.5x Biotechnology median of 22.75%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
-244.00%
Negative 10Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-244.00%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-244.00%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2826.88%
Asset growth of 2826.88% while Biotechnology median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
26.94%
BV/share growth of 26.94% while Biotechnology is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
3.22%
Debt growth of 3.22% while Biotechnology median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-10.82%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.